Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease

No Thumbnail Available
Authors
Schrauben, Michael
Dempster, Emma
Lunnon, Katie
Journal
Brain Pathology
Type
Journal Article
Publisher
Wiley
Rights
© 2020 International Society of Neuropathology.
Recent studies have highlighted a potential role of genetic and epigenetic variation in the development of Alzheimer's disease. Application of the CRISPR-Cas genome-editing platform has enabled investigation of the functional impact that Alzheimer's disease-associated gene mutations have on gene expression. Moreover, recent advances in the technology have led to the generation of CRISPR-Cas-based tools that allow for high-throughput interrogation of different risk variants to elucidate the interplay between genomic regulatory features, epigenetic modifications, and chromatin structure. In this review, we examine the various iterations of the CRISPR-Cas system and their potential application for exploring the complex interactions and disruptions in gene regulatory circuits that contribute to Alzheimer's disease.
Citation
Schrauben M, Dempster E, Lunnon K. Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease. Brain Pathol. 2020 Sep;30(5):992-1004.
Note